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Budding of HIV-1 requires the binding of the PTAP
late domain of the Gag p6 protein to the UEV domain
of the TSG101 subunit of ESCRT-I. The normal
function of this motif in cells is in receptor downregu-
lation. Here, we report the 1.4–1.6 A˚ structures of the
human TSG101UEV domain alone andwithwild-type
and mutant HIV-1 PTAP and Hrs PSAP nonapepti-
des. The hydroxyl of the Thr or Ser residue in the
P(S/T)AP motif hydrogen bonds with the main chain
of Asn69. Mutation of the Asn to Pro, blocking the
main-chain amide, abrogates PTAP motif binding
in vitro and blocks budding of HIV-1 from cells.
N69P and other PTAP binding-deficient alleles of
TSG101 did not rescue HIV-1 budding. However,
the mutant alleles did rescue downregulation of
endogenous EGF receptor. This demonstrates that
the PSAP motif is not rate determining in EGF
receptor downregulation under normal conditions.
INTRODUCTION
Most membrane-enveloped animal viruses, including HIV-1,
require the assistance of the host Endosomal Sorting Complex
Required for Transport (ESCRT) machinery in order for nascent
virions to be severed from the host cell membrane (Bieniasz,
2009; Chen and Lamb, 2008; Morita and Sundquist, 2004). The
normal functions of the ESCRT complexes are in the sorting of
ubiquitinated transmembrane proteins (Raiborg and Stenmark,
2009), the budding of cargo-rich membrane patches into the
lumen of the endosomes (Hurley and Hanson, 2010; Wollert
and Hurley, 2010), and the severing of the narrow membrane
necks (Hurley and Hanson, 2010; Wollert et al., 2009). The initial
recognition and clustering of ubiquitinated receptors is primarily
the task of ESCRT-0 (Hurley and Hanson, 2010; Wollert and
Hurley, 2010), bud formation the task of ESCRT-I and –II (Wollert
and Hurley, 2010), and neck severing is carried out by ESCRT-III
(Wollert et al., 2009). All of these steps are required for the normal1536 Structure 18, 1536–1547, November 10, 2010 ª2010 Elsevier Lfunctioning of the ESCRT pathway in receptor downregulation,
but only the membrane neck severing step appears to be
required for viral budding (McDonald and Martin-Serrano,
2009). So far as is known, no virus directly recruits the ESCRT-
III membrane scission machinery. Rather, viral proteins recruit
various ESCRT components via short peptide motifs known as
late domains (Freed, 2002). There are three major classes of
late domains, of the form PPXY, YPXnL, and P(S/T)AP. The
most widespread of the late domains is the P(S/T)AP motif,
which binds to the ubiquitin E2 variant (UEV) domain of the
TSG101 subunit of ESCRT-I. The Gag p6 protein of HIV-1
contains a single PTAP motif whose presence and binding to
TSG101 is essential for efficient viral budding (Demirov et al.,
2002a, 2002b; Garrus et al., 2001; Martin-Serrano et al., 2001;
VerPlank et al., 2001). A single PSAP motif in the Hrs subunit of
ESCRT-0 has also been shown to bind to the TSG101 UEV
domain (Bache et al., 2003; Lu et al., 2003; Pornillos et al., 2003).
The ESCRT-I complex is a 1:1:1:1 heterotetramer of the
subunits TSG101 (Vps23 in yeast), VPS28, VPS37, and MVB12
(Audhya et al., 2007; Morita et al., 2007). In humans, there are
four well-established isoforms of VPS37 and two ofMVB12 (Mor-
ita et al., 2007). TSG101 contains at its N terminus an UEV
domain, an enzymatically inactive variant of an ubiquitin E2
enzyme. The UEV domain of TSG101 is attached by a 50
residue Pro-rich linker to one end of the rigid 180 A˚ long
ESCRT-I core (Kostelansky et al., 2007). In addition to binding
to the P(S/T)AP motif, the UEV domain also binds to ubiquitin at
a nonoverlapping site (Sundquist et al., 2004; Teo et al., 2004).
The solution structure of the UEV complex with the HIV-1 PTAP
peptide has been invaluable as the structural underpinning for
P(S/T)XP late domain activity. However, this structure does not
explain certain key aspects of the structure-activity relationships.
A Ser or Thr is always present at the second position in the motif,
and its presence is required for binding (Garrus et al., 2001;
Martin-Serrano et al., 2001; Schlundt et al., 2009) and function
(Huang et al., 1995; Martin-Serrano et al., 2001). However, the
Thr hydroxyl in the NMR structure is pointed toward solution
and makes no hydrogen bonds with the protein.
Current anti-HIV-1 therapies for treating AIDS primarily target
the three viral enzymes reverse transcriptase, protease, and in-
tegrase. Despite the effectiveness of these therapies, strainstd All rights reserved
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Figure 1. Structure of TSG101 UEV and HIV-1 p6 Peptide
(A) Schematic representations of human TSG101 and HIV-1 Gag. Abbreviations within TSG101 are UEV (ubiquitin E2 variant) and SB (‘‘steadiness’’ box). Viral
protease cleavage sites are indicated by vertical lines and the names of resulting proteins are shown. The location of the PTAP peptide in p6Gag is indicated.
(B) Amino acid sequence and secondary structure of TSB101 UEV. The residues involved in PTAP peptide binding are colored in green.
(C) Overall structure of TSG101 UEV and HIV p6 peptide.
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The ESCRT-I/HIV-1 Gag PTAP Interactionresistant to inhibitors of all three of the HIV-encoded enzymes
have been isolated (Shafer and Schapiro, 2008). Much of the
effort invested in mechanistic studies of the ESCRT system
has been motivated by the long-term need to develop new
potential therapeutic targets, given the likelihood that HIV-1 will
evolve in future years to evade current treatments. Although it
is more difficult to inhibit peptide-protein interactions than to
block enzyme activity, the PTAP-TSG101 interaction remains
the most promising potential therapeutic target involving the
budding step of the viral life cycle (Liu et al., 2008; Tavassoli
et al., 2008; Waheed and Freed, 2008). Indeed, stable expres-
sion in culture of a dominant-negative fragment of TSG101
blocks the replication of feline immunodeficiency virus (FIV),
a lentivirus that like HIV-1 uses a P(S/T)AP-TSG101 interaction
to bud from cells (Luttge et al., 2008).
Despite the interest in targeting the p6-TSG101 interaction as
a novel antiviral strategy, prospects have been clouded by
concerns that this same interaction is involved in the normal
function of TSG101 in receptor downregulation. TSG101 was
originally described as a tumor susceptibility gene (Li andCohen,
1996), and loss of TSG101 leads to tumors inDrosophila (Moberg
et al., 2005). It has been widely assumed that the binding of
human ESCRT-I with ESCRT-0 (Bache et al., 2003; Lu et al.,
2003; Pornillos et al., 2003) would be critical for the downregula-
tion of proliferative receptors such as EGF receptor (EGFR), and
this concern has to some extent deterred efforts to target this
interaction for therapeutic purposes. However, conflictingStructure 18, 1536–154reports have been presented on the requirement of this interac-
tion for EGFR downregulation (Demirov et al., 2002a; Lu et al.,
2003). Because of the uncertainties concerning the structural
details of the complex and the effect of its disruption on EGFR
downregulation, we obtained high-resolution crystal structures
of the TSG101 UEV domain with and without P(S/T)AP-contain-
ing peptides and reexamined its functions using RNAi knock-
down/rescue experiments. The high-resolution crystal struc-
tures were used to design RNAi-resistant alleles coding for
mutants selectively impaired in P(S/T)AP motif binding to the
UEV domain. The results show that the PTAP-UEV interaction
is required for HIV-1 budding, as expected. However, we found
that the interaction is not a rate-limiting step in EGFR downregu-
lation. Challenges also remain in the design of pharmacologically
effective inhibitors to block protein-peptide binding. Having in
hand high-resolution structures of the complex to be targeted
will be a valuable addition to the tool kit for the challenging but
important goal of PTAP inhibitor design.
RESULTS
Structure of the HIV-1 Gag PTAP Peptide-UEV
Domain Complex
In order to obtain crystals of the UEV domain (Figure 1A) in
complex with peptides, the six residue loop between b1 and
b2, which is flexible in the absence of bound ubiquitin, was re-
placed by the linker Gly-Thr-Gly (Figure 1B). The deletion does7, November 10, 2010 ª2010 Elsevier Ltd All rights reserved 1537
Table 1. Statistics of Data Collection and Crystallographic Refinement
Crystal
HRS (residues 346–354)
PTPSAPVPL Apo UEV
Wild-type HIV-1
Gag PEPTAPPEE
P7A Mutant HIV-1
Gag PEATAPPEE
Constructs TSG101 (2–145) TSG101 (2–145) TSG101 (2–145) TSG101 (2–145)
43–48 GTG 43–48 GTG 43–48 GTG 43–48 GTG
Space group, unit cell P212121 P21 P212121 P212121
a = 33.6 A˚, b = 45.1 A˚, a = 33.6 A˚, b = 45.7 A˚, a = 33.5 A˚, b = 45.8 A˚, a = 33.5 A˚, b = 45.8 A˚,
c = 87.7 A˚ c = 50.2 A˚
b = 108.3
c = 85.4 A˚ c = 89.0 A˚
X-ray source APS 22-ID APS 22-ID APS 22-BM APS 22-ID
Wavelength (A˚) 1.0000 1.0000 1.0000 1.0000
Resolution (A˚) (last shell) 1.4 (1.40–1.42) 1.5 (1.50–1.53) 1.6 (1.60–1.63) 1.6 (1.60–1.63)
No. of unique reflections 25,924 22,570 17,689 18,234
I/s(I)s (last shell) 28.9 (3.6) 47.5 (25.3) 30.4 (4.1) 25.3 (6.6)
Rsym (%) 6.3 (34.3) 3.9 (9.2) 7.6 (32.8) 6.3 (23.2)
Data completeness (%) 96.1 (97.3) 97.1 (96.2) 98.8 (93.5) 97.1 (90.5)
Refinement
R factor (%) 20.7 (24.1) 21.5 (21.0) 19.9 (24.0) 20.6 (21.9)
Free R factor (%) 22.4 (24.5) 23.2 (22.8) 23.5 (27.8) 23.0 (27.4)
Rms bond length (A˚) 0.005 0.005 0.005 0.005
Rms bond angle () 1.3 1.3 1.3 1.3
Average B value (A˚2) 15.8 15.2 17.8 15.6
Number of atoms Protein 1195; water 214 Protein 1121; water 217 Protein 1207; water 156 Protein 1193; water 125
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The ESCRT-I/HIV-1 Gag PTAP Interactionnot appear to have affected the overall structure, as the 1.5 A˚
resolution structure of the unliganded loop deletion construct
is essentially superimposable on the 2.26 A˚ resolution X-ray
structure of the wild-type unliganded UEV domain (Palencia
et al., 2006). The superposition has an rmsd of 0.5 A˚ for 122
Ca positions, including the entire domain except for the b1/b2
linker and the extreme C terminus. The structure of the human
TSG101 UEV domain bound to the HIV-1 Gag p6 nonapeptide
PEPTAPPEE was determined at 1.6 A˚ resolution by molecular
replacement with the unliganded wild-type UEV (Palencia
et al., 2006) (Figure 1C and Table 1). The HIV-1 Gag PTAP
peptide binds to a groove on the UEV domain formed between
the b2/b3 hairpin, the b4/b5 loop, and the C-terminal residues,
in the same orientation as seen previously in the solution NMR
analysis (Pornillos et al., 2002a).
The entire HIV-1 p6 nonapeptide is well ordered and visualized
in the binding groove (Figure 2A). Every residue of the peptide
makes contact with the UEV domain via either the main chain,
side chain, or both (Figures 2B and 2C), with the possible excep-
tion of the first residue, Pro5. Contact distances with Pro5 are on
the borderline of significance. The main-chain carbonyl of Glu6
hydrogen bonds to the side chain of Asn69, although at 3.3 A˚
and exposed to solvent, the energetic contribution of this inter-
action is probably marginal. The first residue of the PTAP motif,
Pro7, is wedged in a shallow hydrophobic pocket formed by the
side chains of Thr58, Pro71, and Thr92. Both Thr residues
contribute their g-methyl groups to the pocket, and their hydroxyl
groups point away from it. The Pro7 pocket is open on the side
corresponding to the N terminus of the peptide, leaving the
Pro7 side chain partially exposed to solvent. The main-chain
amide of the critical motif residue Thr8 forms a hydrogen bond1538 Structure 18, 1536–1547, November 10, 2010 ª2010 Elsevier Lwith the main-chain carbonyl of Asn69. The side-chain hydroxyl
group of Thr8 forms a relatively short 2.8 A˚ hydrogen bond with
the main-chain amide of Asn69. The g-methyl of the Thr8 side
chain points toward solvent and has no direct interactions with
the domain, however. The methyl group of the conserved Ala9
side chain is buried in a tightly packed pocket formed by the
side chains of Ile70,Met95, and Val141. The tight packing around
the Ala side chain explains the critical requirement for an Ala at
this position in the motif. The Ala main-chain carbonyl makes
a 2.6 A˚ hydrogen bond to the side chain of Ser143. The side chain
of the last conserved motif residue, Pro10, is almost completely
buried in a deep hydrophobic pocket. The floor of the pocket is
formed by the side chain of Pro139, while the walls are formed
by the side chains of Tyr63, Tyr68, and Phe142. The Pro10
main-chain carbonyl forms a hydrogen bondwith themain-chain
amide of Ser143. The side chain of Pro11 comes within 3.7 A˚ of
the side chain of Tyr68. The side chains of Glu12 and Glu13 are
in the vicinity of the basic side chains of Lys98 andArg64, respec-
tively, though these residues are highly solvated and probably
contribute only marginally to binding affinity.
Conformational Changes Induced by Peptide Binding
The high-resolution structure determination of both the HIV-1
PEPTAPPEE complex and the unliganded UEV structure
using the same UEV construct allows a detailed analysis of
structural changes on binding. These changes are modest in
magnitude. The largest change is a rotamer shift in the phenyl
side chain of Phe142 such that it makes contact with Pro10
(Figure 2D). The Phe142 side-chain atoms move by as much
as 8 A˚ in this shift, thereby creating the binding pocket for
Pro10 by induced fit. The C-terminal residues Arg144 andtd All rights reserved
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Figure 2. Binding of HIV-1 PTAP Peptide
(A) 1.6 A˚ simulated-annealing omit map of the HIV-1 PTAP peptide with the final model superimposed.
(B) Electrostatic surface representation of the UEV-HIV peptide. The electrostatic surface was colored using APBS tools of PyMOL software.
(C) A ball and stick representation of the PTAP peptide binding.
(D) Structural superposition of apo UEV and HIV-1 PTAP peptide complex.
(E) Structural comparison of X-ray structure (this study) and the NMR structure (PDB id: 1M4Q) of TSG101 UEV-HIV PTAP complex.
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The ESCRT-I/HIV-1 Gag PTAP InteractionPro145 of the UEV domain are only ordered well enough to
model in the peptide complex, not in the unliganded structure.
For residues 142-143, B factors drop from the 25–40 A˚2 range
to the 12–18 A˚2 for the peptide complex. The side chain of
Met95 moves by a maximum of 2 A˚, and the B factors drop
from the range of 33–43 to 14–21 A˚2.Structure 18, 1536–154Comparison of Crystal and Solution NMR Structures
of the HIV-1 Peptide Complex
As would be expected for a solution NMR/X-ray crystallo-
graphic comparison, the Ca rmsd of 1.6 A˚ between the 126
most similar Ca positions of the two structure is substantially
higher than that between crystal structures of the UEV domain7, November 10, 2010 ª2010 Elsevier Ltd All rights reserved 1539
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constructs (0.4–0.5 A˚ for 140 Ca positions). The largest
differences in the path of the main chain, of up to 7 A˚, are in
the b1/b2 (also influenced by the loop deletion construct), b3/
b4, and a3/a4 loops, which are all distal to the peptide binding
site. Near the peptide-binding site, all Ca positions are within
2 A˚ in of each other in the overlaid structures, and most are
closer. Within the peptide-binding pocket, the van der Waals
contacts around the Pro7 side chain are essentially the same
in both structures. Indeed, throughout the peptide-binding
site, the qualitative conclusions about the identity of van der
Waals interaction partners drawn from the NMR structure are
consistent with the X-ray structure. In the NMR analysis, the
Thr 8 hydroxyl proton resonance was observed, showing that
it is protected from solvent exchange (Pornillos et al., 2002a),
and consistent with a strong and stable hydrogen-bonding
interaction. The hydrogen-bonding partner of the Thr8 side
chain could not be identified directly from the spectra (Pornillos
et al., 2002a). It was inferred from the derived structures that Thr
8 might donate a hydrogen bond to the backbone carbonyl of
Arg 144 and accept one from the O of Ser 143 (Pornillos
et al., 2002a). However, these interactions were not observed
in all calculated structures because the Ser 143 and Arg 144
positions were not precisely defined by the NOE data (Pornillos
et al., 2002a). The Pornillos et al. (2002a) study notes that the
nature of the hydrogen bond of the hydroxyl is not resolved
by the NMR analysis.
Overall, the main difference between the two structures is in
the conformation of the central portion of the peptide. The
peptide group connecting Pro7 and Thr8 is flipped 180 between
the crystal and the averaged NMR structure (Figure 2E), thus the
hydrogen bonds involving this peptide group and the Thr side
chain are not apparent in the solution structure. The peptide
connecting Thr8 and Ala9 is also in a sharply different orientation.
The conserved residues of the motif have a regular b-conforma-
tion in the X-ray structure, while the peptide is sharply kinked
about the Thr residue in the NMR structure. Most of the key
hydrogen-bonding interactions were therefore missed in the
NMR analysis. The improved accuracy of the high-resolution
X-ray analysis permits the hydrogen bond network to be
described for the first time.
Structure of the ESCRT-0 Subunit Hrs PSAP Motif
Peptide-UEV Domain Complex
The Hrs PSAP motif nonapeptide corresponding to residues
346-354 of human Hrs binds in the same overall geometry as
the HIV-1 peptide (Figures 3A and 3B). The replacement of the
HIV-1 Glu6 by Hrs Thr347 causes essentially no change in the
structure, as both side chains point toward solvent. Likewise,
the replacement of HIV-1 Thr8 by Hrs Ser has no effect on the
structure, since the g-methyl of the Thr8 points toward solvent.
The key Ala and final Pro residues of the motif are in identical
positions. The replacement of Pro11 by Val results in the loss
of a van der Waals interaction with Tyr68. The only substantial
structural changes are seen at the C-terminal end of the peptide,
where Glu12 and Glu13 of HIV-1 Gag are replaced by Pro and
Leu in Hrs. The Hrs Pro forms a new contact that pushes the
C-terminal Pro145 of the UEV domain away from its position in
the HIV-1 complex by 1.5 A˚. The loss of the acidic Glu13 at the1540 Structure 18, 1536–1547, November 10, 2010 ª2010 Elsevier LC terminus of the peptide breaks the charge pair interaction
with Arg64. The guanidinium group of the Arg side chain moves
5 A˚ away from its position in the HIV-1 structure, carrying with it,
to a lesser extent, Gly65 and Asn66.
Structure of the HIV-1 P7A Mutant in Complex
with the UEV Domain
The replacement of Pro7 by Ala leads to the loss of van derWaals
contacts with the g-methyl groups of Thr58 and Thr92 (Figures
3C and 3D). The comparison of the wild-type and P7A mutant
structures shows that the UEV domain structure is identical at
these two positions. The UEV structure does not relax at these
positions when the contacts are lost, and therefore conforma-
tional changes do not mitigate the energetic cost of the lost
interactions. Attempts weremade to cocrystallize other peptides
altered at all of the conserved motif positions, but with the
exception of P7A, the rest of the mutant peptides yielded either
no crystals or unliganded complexes.
Isothermal Titration Analysis of Binding Determinants
The HIV-1 PTAP nonapeptide bound the UEV domain in solution
with a Kd value of 50 mM (Figure 4A and Table 2). This is in
reasonable agreement with the value of 27 mM obtained for
immobilized GST-p6 residues 1–27 under otherwise similar
conditions (Pornillos et al., 2002b). Consistent with previous
reports (Pornillos et al., 2002b), the mutants Y63A and M95A,
designed to remove van der Waals interactions with the peptide,
exhibited sharply reduced and essentially no binding, respec-
tively (Figure 4A and Table 2). The N69P mutant was designed
as a key test of the newly described hydrogen bond network
model. This mutation was predicted to remove two hydrogen
bonds. Of the two, the hydrogen bond between the main-chain
amide of Asn69 with the side-chain hydroxyl of Thr8 was judged
the more important, hence the choice of Pro as the unique cyclic
nature of this side-chain blocks this interaction. We found that
the N69P mutation equals M95A in potently blocking binding
(Figure 4A and Table 2). Binding of mutants to the Hrs PSAP
peptide was not tested, because these mutations are all at sites
that interact with the conserved central portion of the peptide
common to HIV-1 and Hrs. Therefore the relative effects of the
mutations are expected to be identical. The S143A mutant
was designed as another test of the role of hydrogen bonding.
S143A did not significantly decrease binding. This may be
attributable to the very short oxygen-oxygen distance in this
hydrogen bond. At 2.6 A˚, these atoms are unusually close for
a pair in which neither partner is charged, and the resulting
steric strain may offset the otherwise favorable energy of the
hydrogen bond.
We went on to quantify the effects on affinity of altering the
conserved motif residues. The conserved Ala9 of the motif is
absolutely required for binding (Figure 4B and Table 2), consis-
tent with its conservation and with peptide screening results
(Schlundt et al., 2009). Assuming that the surrounding protein
does not relax, the A9G mutation is expected to create an
energetically unfavorable cavity the size of one methyl group.
Such cavities are too small and hydrophobic to be filled with
water, and the energetic cost of the resulting vacuum is
presumably responsible for the loss of affinity (Eriksson et al.,
1992). A9M abrogates binding by the opposite principle,td All rights reserved
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Figure 3. Recognition of HRS and HIV-1 Peptides by UEV Domain
(A) Binding of HRS peptide on UEV domain.
(B) Structural superposition of HRS and HIV p6 peptides.
(C) Superposition of the wild-type HIV-1 p6 peptide and the P7A mutant peptide.
(D) Surface representation of the UEV-P7A peptide binding.
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The ESCRT-I/HIV-1 Gag PTAP Interactionintroducing a steric collision into the binding site (Figure 4B and
Table 2). Consistent with expectation, HIV-1 nonapeptide
mutants T8A and P10A had no detectable binding (Figure 4B
and Table 2).
Finally, we evaluated the effects of altering the less
conserved residues at the start of and surrounding the HIV-1
PTAP motif. Pro7 is not as critical for binding as the other resi-
dues in the PTAP motif (Schlundt et al., 2009), and both P7A
and P7S mutants were tested (Figure 4B and Table 2). The
P7A mutant leads to a less than 3-fold reduction in affinity,
consistent with the results of Schlundt et al. (2009). Indeed,
Pro7 buries 86 A˚2 of solvent accessible surface area in the
UEV domain interface, compared with 115 A˚2 for the more crit-
ical Pro10. The P7S mutant was designed on the basis of anStructure 18, 1536–154observation by one of us (X.R., unpublished data) that the
central region of Hrs can bind to the UEV domain even when
the Hrs PSAP region is deleted. This region contains two
SSAP sequences. The finding that P7S has measurable binding
explains how this sequence is able to bind to the UEV domain in
the absence of an intact PSAP motif. The P11A peptide was
made to investigate the role of this residue, which is replaced
by a Val in the Hrs sequence. P11A has a Kd greater by a factor
of 3.5 as compared with wild-type (Figure 4B and Table 2).
Indeed, the affinity of P11A, which does not inhibit HIV-1
budding (Demirov et al., 2002b), for the UEV domain is similar
to that of the Hrs nonapeptide itself, which is 6-fold lower
than that of the wild-type HIV-1 nonapeptide (Figure 4B and
Table 2). The 6-fold affinity difference between HIV-1 Gag and7, November 10, 2010 ª2010 Elsevier Ltd All rights reserved 1541
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Figure 4. Isothermal Titration Calorimetry (ITC) of
the UEV-P(S/T)AP Interaction
(A) Binding of Gag PTAP peptide to wild-type and mutant
TSG101 UEV domains. The inset showed the differential
heat released when Gag PTAP peptide (0.38 mM) was in-
jected into the TSG101 UEV wild-type solution (4 mM) in
2.1 ml aliquots.
(B) ITCmeasurement of the binding of Gag PTAPwild-type
and mutant peptides to TSG101 UEV domain. Error bars
represent the standard deviation of three measurements.
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The ESCRT-I/HIV-1 Gag PTAP InteractionHrs peptides is nearly identical to the 7-fold difference reported
previously (Pornillos et al., 2003). A corresponding peptide from
Vps27, which is the yeast counterpart of Hrs, and has an anal-
ogous interaction with yeast ESCRT-I, does not bind to the
human UEV domain, however. Taken together, these results
show consistency with the structural findings, sequence
conservation, and previous in vitro quantitative and library-
based binding analyses, and add to the tools available to probe
function in vivo.
Gag PTAP Motif Binding to TSG101 Is Required
for HIV-1 Release
To measure the effect of TSG101 PTAP-binding site mutations
on HIV-1 release, metabolic radio-immunoprecipitation of cells
expressing WT HIV-1 was performed. In the control cultures,
HeLa cells were transfected with nontargeting siRNA and rela-1542 Structure 18, 1536–1547, November 10, 2010 ª2010 Elsevier Ltd All rights reservtive virus release efficiency was set to 100%.
Knockdown of TSG101 resulted in a 5-fold
reduction in virus release efficiency (Figure 5A).
The budding defect induced by TSG101
depletion was also accompanied by the charac-
teristic (Gottlinger et al., 1991; Huang et al.,
1995) accumulation of the p25 processing
intermediate relative to mature p24 (CA) (see
p25 to p24 levels in the cell-associated
panel of Figure 5). The virus release defect
induced by TSG101 depletion could be res-
cued by providing exogenous, siRNA-resistant
TSG101, such that the virus release efficiency
was restored to80% that of the control. Muta-
tions in the TSG101 UEV domain at positions
Y63, N69, and M95 abrogated the ability of
the siRNA-resistant TSG101 to rescue virus
release (Figure 5B). The essentially complete
lack of rescue is consistent with the complete
loss of binding observed by ITC. The transfec-
tion efficiencies of the Y63, N69, and M95
mutant expression vectors were comparable
to those of the WT, and even at high DNA input
levels these three mutants failed to rescue virus
release in Tsg101-depleted cells (data not
shown). The S143A mutant partially rescued
virus release, to levels approximately 2-fold
that observed in the control cultures. The partial
effect of the S143A mutant on virus release
strikingly illustrates the sensitivity of virus
release to small perturbations in affinity, giventhat the effects of this mutation on equilibrium binding in vitro
are marginal.
Hrs PSAP Motif Binding to TSG101 Is Not Required
for EGFR Downregulation
In order to probe the role of the P(S/T)APmotif binding site on the
TSG101 UEV domain in receptor downregulation, endogenous
TSG101 was silenced in HeLa cells as described above. Rescue
constructs encoding wild-type TSG101 and the four mutants
assessed above were tested for function. Following 60 min
stimulation of serum-starved cells with 50 or 100 ng/ml EGF,
EGFR levels dropped sharply in cells not treated with siRNA
(Figure 6A). Knockdown of TSG101 prevented the decrease in
EGFR levels upon treatment with EGF (Figure 6B and second
lane of Figure 6C). This result demonstrated that TSG101 deple-
tion blocked ESCRT-mediated turnover of activated EGFR.ed
Table 2. Equilibrium Dissociation Constants for the Various ITC
Experiments.
UEV Peptide name Peptide sequence KD (mM)
UEV-WT Gag PTAP-WT 5PEPTAPPEE13 50 ± 0.7
UEV-WT P7A PEATAPPEE 130 ± 4.0
UEV-WT P7S PESTAPPEE 1600 ± 14
UEV-WT T8A PEPAAPPEE N.B.
UEV-WT A9G PEPTGPPEE N.B.
UEV-WT A9M PEPTMPPEE N.B.
UEV-WT P10A PEPTAAPEE N.B.
UEV-WT P11A PEPTAPAEE 170 ± 15
UEV-WT HRS-PSAP PTPSAPVPL 290 ± 42
UEV-WT Vps27-PSDP LAPSDPPYP N.B.
UEV-Y63A Gag PTAP-WT PEATAPPEE N.B.
UEV-N69P Gag PTAP-WT PEATAPPEE N.B.
UEV-M95A Gag PTAP-WT PEATAPPEE N.B.
UEV-S143A Gag PTAP-WT PEATAPPEE 53 ± 2.8
N.B., no binding.
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transfection of the siRNA-resistant allele (WT-R, third lane in
Figure 6C). Each of the mutant constructs was then tested (lanesFigure 5. Mutation of the TSG101 UEV Domain Disrupts HIV-1 Release
(A) HeLa cells were transfectedwith anti-TSG101 siRNA to knock down endogeno
ular clone pNL4-3 and vectors expressing siRNA-resistant WT or mutant TSG101
virus lysates were immunoprecipitated with anti-HIV-1 Ig. Cell-associated and v
(B) Relative virus release efficiency calculated as p24 (CA) in the virus supernatan
three independent experiments.
(C) Anti-TSG101 western blot, demonstrating efficient depletion of endogenous
Structure 18, 1536–1544–7, Figure 6C). The TSG101 mutants were as effective as the
wild-type in rescuing the effect of the knockdown, demon-
strating that they retained full function in EGFR downregulation.DISCUSSION
The high-resolution crystal structures of TSG101 UEV domain-
peptide complexes, together with in vitro binding studies and
previous work, provide a richly detailed picture of the binding
determinants for the human TSG101 UEV domain. If the second
Pro is defined as the ‘‘most important’’ residue for reference
purposes and numbered ‘‘0’’ (Aasland et al., 2002), the minimal
required motif would be Pro/Ala at –3, Ser/Thr at –2, Ala at –1,
and Pro at 0. The ‘‘preferred’’ motif would additionally have a
Pro at +1. These determinants are set by well-defined hydro-
phobic pockets, as described here and previously (Pornillos
et al., 2002a), together with the hydrogen-bonding network
described in this study. Regarding the importance of the Pro
at +1, alignment of PT/SAPmotifs fromdiverse enveloped viruses
indicates that the presence of a Pro at this position is highly, but
not absolutely, conserved.Thefinal (+1)Pro in theP(S/T)APPmotif
is foundacrossallmajor cladesofHIV-1and isalso found inHIV-2,
SIVagm SIVcpz, SIVgor, and SIVsmm (http://www.hiv.lanl.gov/
content/sequence/HIV/COMPENDIUM/2010/plvprot.pdf). Visnaus Tsg101 expression, and 24 hr later were cotransfectedwith the HIV-1molec-
as indicated. Cells were metabolically labeled with [35S]Met/Cys and cell and
irion-associated immunoprecipitates were quantitated by autoradiography.
t divided by total Gag protein in the cell and virus. Error bars indicate SD from
TSG101 protein levels.
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Figure 6. A Functional PTAP Binding Site in
TSG101 Is Not Needed for EGFR Downregu-
lation
(A) HeLa cells were starved in serum-free medium
for 1 hr at 37C and then incubated with EGF (50 or
100 ng/ml) for 1 hr at 37C. Protein extracts were
analyzed by immunoblotting with a polyclonal anti-
body to EGFR (RK-2) and a monoclonal antibody
to TSG101.
(B) After a 72 hr treatment with TSG101 siRNAi,
cells were starved in serum-free medium for 1 hr
at 37C and then incubated with 50 ng/ml EGF
for 1 hr at 37C. Mock and TSG101KD extracts
were analyzed by immunoblotting for EGFR and
TSG101.
(C) After a 48 hr treatment with TSG101 siRNAi,
cells were transfected with TSG101 constructs
(rescue). At 20 hr posttransfection, cells were
starved in serum-free medium for 1 hr at 37C
and then incubated with 50 ng/ml EGF for 1 hr at
37C. Extracts were analyzed by immunoblotting
for EGFR and GFP-TSG101 with a polyclonal anti-
body to GFP. Transfection efficiency was higher
than 50% in each experiment confirmed by fluo-
rescence microscopy visualizing cells expressing
GFP-TSG101.
(D) Levels of EGFR were quantitated by X-ray film
densitometry and percentages of undegraded
EGFR upon EGF induction were plotted. Bars
represent the mean ± SD from three independent
experiments.
Structure
The ESCRT-I/HIV-1 Gag PTAP Interactionvirus, bovine immunodeficiency virus, and feline immunodefi-
ciency virus all encode P(S/T)APP motifs, as does Ebola virus,
whereas in HTLV-1 this motif is PTAPQ. We have studied the
effects of mutating the +1 Pro in HIV-1 (Demirov et al., 2002b)
and find that while particle budding occurs efficiently upon
PTAPP to PTAPE mutation, the Gag processing intermediate
p41 accumulates, suggesting a delay in budding kinetics.
The ability of HIV-1 to rapidly develop resistance to drugs has
leant urgency to the discovery of alternative therapeutic targets.
From the initial discovery of the HIV-1 Gag PTAP-TSG101 inter-
action, ESCRT-I has appeared to be one of the more critical1544 Structure 18, 1536–1547, November 10, 2010 ª2010 Elsevier Ltd All rights reservedhost-pathogen interactors in the HIV life
cycle, and thus a promising target.
However, efforts at developing PTAP
inhibitors have suffered to some extent
from the impression that such inhibitors
might also interfere with the downregula-
tion of proliferative receptors such as
EGFR and thus promote tumorigenesis.
The most influential study along these
lines was based on antisense inhibition
of TSG101 and rescue with UEV domain
mutants that included the Y63A and
M95A mutants also studied here
(Lu et al., 2003). In the Lu et al. report,
downregulation of transfected EGFR
was monitored following prolonged
(90 min) stimulation with very high levels
(150 ng/ml) of EGF. The Lu et al. studydoes establish that PSAP recognition by the UEV is required
under at least some conditions. We infer that PSAP recognition
is likely to be at least involved, if not required, under other condi-
tions. In the current study, endogenous EGFR was monitored
following treatment with 50–100 ng/ml EGF for 60 min, which is
at the high end of the range conventionally used in EGFR degra-
dation assays. These results suggest to us that under normal or
even moderately intense stimulatory conditions, the Hrs PSAP-
TSG101 UEV interaction is not rate limiting, although it may
become rate limiting under conditions of exceptionally intense
loading with highly stimulated exogenous receptors. The results
Structure
The ESCRT-I/HIV-1 Gag PTAP Interactionin this study are consistent with the previous observation that
overexpression of the TSG101 UEV domain fragment, which
potently blocks HIV-1 budding, does not inhibit EGFR degrada-
tion (Demirov et al., 2002a).
The interaction between TSG101 UEV and Hrs PSAP is not
required for EGFR downregulation under normal conditions,
even though TSG101 (Babst et al., 2000; Lu et al., 2003) and
Hrs (Bishop et al., 2002; Chin et al., 2001; Lu et al., 2003) are
required individually. The yeast counterparts of TSG101 and
Hrs are the Vps23 and Vps27 subunits of ESCRT-I and
ESCRT-0, respectively. ESCRT-0 is responsible for organizing
ubiquitinated proteins into clusters on the endosomal
membrane, while ESCRT-I cooperates with ESCRT-II to create
buds into which the ubiquitinated cargo are sorted (Wollert and
Hurley, 2010). Loss of the PSDP motifs in yeast ESCRT-0 that
are required to bind to yeast ESCRT-I reduces, but does not
completely eliminate, colocalization of ESCRT-I and -II (Wollert
and Hurley, 2010). Residual colocalization could be mediated
by some other part of the structures, or by an indirect effect
such as lipid or cargo clustering. Indeed, there have been several
reports suggesting that other parts of the ESCRT-0 and -I
complexes interact with one another (Bouamr et al., 2007; East-
man et al., 2005; Stuchell et al., 2004). It seems likely that PSAP-
mediated colocalization of human ESCRT-0 and ESCRT-I does
occur during normal EGFR sorting, but is not the rate-deter-
mining step, and therefore disrupting PSAP-TSG101 binding
has no effect on EGFR downregulation. It is currently unknown
what the role of this interaction is in downregulation of other
cell surface proteins.
In summary, the results described here provide clear-cut
validation for the concept that HIV-1 budding inhibitors targeted
at the PTAP binding site of human TSG101 will not necessarily
disrupt certain host functions, such as EGFR downregulation.
The ESCRT system has other host functions in addition to
receptor downregulation, such as cytokinesis (McDonald and
Martin-Serrano, 2009), but Hrs is not currently thought to have
a role in this pathway. Nevertheless, the M95A mutant of
TSG101 has been reported to have a partial cytokinesis pheno-
type (Carlton and Martin-Serrano, 2007), and the possibility of
PTAP inhibitor effects on cytokinesis is a concern that still needs
to be addressed. Inhibitor design efforts, whether through purely
in silico screening or through the use of structural analysis as an
adjunct to traditional medicinal chemistry approaches, stand to
benefit from having the most accurate possible structures of
the target complexes. The structures reported here, at up to
1.4 A˚ resolution, provide the first accurate details of the
hydrogen-bonding network in the PTAP binding site and should
be an important addition to the PTAP inhibitor design toolkit.EXPERIMENTAL PROCEDURES
Protein Expression and Purification
DNA coding for the human TSG101 UEV domain (residues 2–145) was subcl-
oned into the pGST2 vector (Sheffield et al., 1999). Tsg101 UEV was tagged
with an N-terminal GST followed by a tobacco etch virus (TEV) protease
cleavage site. In order to improve the crystallization properties of the UEV
domain, 6 residues (residues 43–48, VFNDGS) in the b1-b2 loop were mutated
to Gly-Thr-Gly. The plasmid was transformed into Escherichia coli strain BL21
(DE3) Star and expressed overnight at 30C. Cells were resuspended in 1X
PBS buffer and lysed by sonication. The GST-UEV was isolated using gluta-Structure 18, 1536–154thione affinity chromatography. The eluate was concentrated and the GST
tag was removed by cleavage with TEV protease. The UEV domain was further
purified by Superdex S200 size exclusion chromatography. The fractions con-
taining the UEV domain concentrated to 10mg/ml in buffer 10mMTris-HCl (pH
8.0), 100 mM NaCl for crystallization.
General Procedure for Solid-Phase Peptide Synthesis
Peptides were synthesized on NovaSynTGR resin (Novabiochem, cat.
no. 01-64-0060) or Rink Amide MBHA resin (Novabiochem, cat. no. 01-64-
0037) by standard Fmoc solid-phase protocols using active ester coupling
methodology in N,N-dimethylforamide (DMF). In summary for each residue,
amino acid (5.0 equivalents based on resin loading), 1-hydroxybenzotriazole
(HOBT) (5.0 eq.) and N,N’-diisopropylcarbodiimide (DIC) (5.0 eq.) was used
for primary amines (single couple, 2 hr) and bromo-tris-pyrrolidino-phospho-
nium hexafluorophosphate (PyBroP) (5.0 eq.) and diisopropylethylamine
(DIEA) (10.0 eq.) (double coupling; 2 hr each) was employed for secondary
amines. The amino terminus was acetylated using acetic anhydride
(10.0 eq.) in DMF. The final resin was washed with DMF, methanol, dichloro-
methane, and ether and then dried under vacuum (overnight). Peptides were
cleaved from the resin (200 mg) by treatment with trifluoroacetic acid: triiso-
propylsilane: H2O (90: 5: 5) (5 ml, 4 hr). The resin was removed by filtration
and the filtrate was concentrated in vacuo, and the peptide was then precipi-
tated by the addition of cold ether and the precipitate was washed with ether.
The resulting white solid was dissolved in 50% aqueous acetonitrile (5 ml) and
purified by reverse phase preparative HPLC using a Phenomenex C18 column
(21 mm dia x 250 mm, cat. no: 00G-4436-P0) with a linear gradient from 0%
aqueous acetonitrile (0.1% trifluoroacetic acid) to 50% acetonitrile (0.1%
trifluoroacetic acid) over 35 min at a flow rate of 10.0 ml/minute (detection at
220 nm). Lyophilization provided products as white powders. The purity of final
peptides was determined by HPLC using a Waters Corp. XBridgeTM BEH130
C18 column (Part no: 186003581) (4.60 mm dia3 250 mm, 5 mm) at a flow rate
of 1.0 ml/minute. Electrospray ionization-mass spectra (ESIMS) were acquired
with an Agilent LC/MS system and Matrix-assisted laser desorption/ionization
(MALDI) mass spectra were acquired with Shimadzu Biotech Axima instru-
ment using a–cyano-4-hydroxycinnamic acid as matrix. High-resolution
mass spectra (HRMS) were obtained from the UCR Mass Spectrometry
Facility, University of California at Riverside.
Crystallization and Crystallographic Analysis
Crystals of UEV-HIV-1 Gag nonapeptide complex were grown by vapor-diffu-
sion methods at 25C over a reservoir of 100 mMHEPES-NaOH (pH 7.5), 25%
PEG 3350, 200 mM NaNO3 for 1 week. Crystals were cryoprotected in Para-
tone and flash frozen using liquid nitrogen. Native data were collected from
a single frozen crystal with an MAR CCD detector at beamline 22-ID and
22-BM, APS. All data were processed and scaled using HKL2000 (HKL
Research). The structure of the complex was determined by molecular
replacement with the program PHASER (McCoy et al., 2007) using the
2.26 A˚ crystal structure of the unliganded human TSG101 UEV domain (PDB
code: 2F0R) (Palencia et al., 2006) as a starting model. The initial model of
UEV peptide was built into the density-modified map using the programs
Coot (Emsley and Cowtan, 2004). The refinement was carried out using CNS
(Brunger et al., 1998) with anisotropic B factor refinement. The final model con-
sisted of one copy of UEV domain and the peptide. There are no residues in
disallowed region of the Ramachandran plot. Structures of the complexes
with the Hrs nonapeptide and the HIV-1 Gag P7A mutant peptide, as well as
the P21 crystal form of the unliganded UEV domain were obtained and solved
as above. All structural figures were prepared using the program PyMOL (W.
Delano, http://pymol.sourceforge.net/).
Isothermal Titration Calorimetry
Purified wild-type andmutant TSG101 UEV domains were dialyzed against the
ITC buffer (20 mM sodium phosphate [pH 7.20] 150 mM NaCl, and 5% glyc-
erol) overnight at 4C. Peptides were dissolved in the same ITC buffer. All
ITC experiments were carried out at 28C on an ITC200 instrument (MicroCal
LLC, Northampton, MA). The sample cell contained 0.2 ml of 300–600 mM
UEV proteins and the peptides (4 or 6.5 mM) were added in 18 injections of
2.1 ml each. Data from peptide injections into buffer blanks were subtracted7, November 10, 2010 ª2010 Elsevier Ltd All rights reserved 1545
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ware (MicroCal). The binding constant (Kd) was fitted as a one-site model.
Rescue Constructs and siRNAs
The full-length HIV-1 molecular pNL4-3 (Adachi et al., 1986) was used to
produce infectious virus in HeLa cells. The siRNA-resistant pIRES2-GFP-
TSG101* (Garrus et al., 2001) was a kind gift from W. Sundquist (University
of Utah). Point mutations in the TSG101 UEV domain were introduced in this
plasmid by site-directed mutagenesis. The anti-TSG101 siRNA corresponds
to the target sequence: 50-AACCTCCAGTCTTCTCTCGTC-30.
Virus Release Assay
HeLa cells were cultured in Dulbecco’s modified Eagle medium with 5% fetal
bovine serum. Anti-TSG101 siRNAs were transfected into HeLa cells with Lip-
ofectamine RNAiMax reagent (Invitrogen). Twenty-four hours after siRNA
transfection, cells were transfected again with anti-TSG101 siRNA and
pNL4-3 and the siRNA-resistant TSG101 expression plasmids using Lipofect-
amine 2000 (Invitrogen). HIV-1 particle release assays were performed as
previously described (Freed and Martin, 1994; Willey et al., 1988). In brief,
transfected cells were starved for 30 min in medium devoid of L-methionine,
L-cysteine, and fetal bovine serum. Cells were then labeled with [35S]Cys/
Met Protein Express Labeling Mix (Perkin Elmer) for 3 hr. Virions were isolated
from the virus supernatant by ultracentrifugation for 1 hr at 45,000 rpm. Virus
and cell lysates were prepared in 0.5% Triton X-100 lysis buffer. Virus and
cell lysates were immunoprecipitated with HIV-1 Ig (NIH AIDS Reference
Reagent Program). Radioimmunoprecipitates were resolved by SDS-PAGE
followed by autoradiography and phosphorimager quantitation. Western blot-
ting was performed on cell lysates using goat polyclonal anti-TSG101 (Santa
Cruz, sc-6037).
EGFR Downregulation Assay
At 48 hr post-RNAi transfection, HeLa cells were transfected with plasmids en-
coding siRNA-sensitive or resistant forms of GFP-TSG101–FLAG (WT or Y63A,
N69P, M95A, S143A mutants). At 20 hr posttransfection, cells were starved in
serum-free medium for 1 hr and then incubated with 50–100 ng/ml EGF
(Upstate) at 37C for 60min. Cells were then washed with cold PBS and imme-
diately lysed. Lysates were subjected to SDS/PAGE and immunoblotting using
a polyclonal antibody to the EGFR (RK-2, a gift from Joseph Schlessinger, Yale
University) and a polyclonal antibody to GFP (Invitrogen).
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